Osteoporosis-osteopenia syndrome in children with transfusion dependent thalassemia
© Ong et al. 2015
Published: 27 October 2015
Osteoporosis-osteopenia syndrome (OOS) is found in more than 50% of thalassemia patients worldwide [1, 2]. Despite appropriate management, thalassemics continue to exhibit a decrease in bone mass due to the multifactorial pathogenesis of OOS in thalassemia . Therefore, this study aims to obtain an insight on the thalassemia patients' perception of OOS and possible lifestyle contributing factors.
64 regularly transfused patients from 2 major Thalassaemia Clinics in Penang aged 10 years and above participated in a 6-week cross-sectional study using a self-administered questionnaire. The questionnaire addressed lifestyle factors (exercise, diet), awareness and symptoms of bone problems. Bone profile information (serum levels of calcium, phosphate, alkaline phosphatase (ALP), 25-hydroxyvitamin D (VitD), and Bone Mineral Density T-scores [BMD]) from patients' records was documented. OOS was considered based on either BMD (lumbar and femur) of <-1.0 and/or VitD of <30ng/ml. Odds ratio was used to compare the relationship between patients' understanding of OOS and presence of symptomatic bone problems. A p-value of <0.05 was taken as significant.
25% of patients had good understanding of OOS in thalassemia. 51.6% were symptomatic, namely 20.3% had history of bone pain or fracture and 42.2% had heights below the 5th percentile. 81.2% exercised frequently and 65.6% consumed low intake of dairy products.
Only 64% of patients had either one or both BMD and VitD results. Of the available results, 87.5% had low VitD and 86.2% had low BMD. Sample serum calcium and phosphate levels were normal while the mean ALP was 164mmol/l. A better understanding on OOS reduced the odds of having symptomatic bone problems, however this was not significant (OR=0.92; p>0.05).
Low-level VitD and BMD results were detected in over 80% of patients who had undergone an OOS diagnostic investigation. This is consistent with the current literature [1, 2]. Many were unaware of OOS and the importance of dairy intake. This suggests that OOS is not well known. The results of this study were limited to the patient's ability to answer the questionnaire and the design of the questionnaire. T-scores were reported instead of Z-scores, which would give a better reflection of OOS in adolescents . ALP could also be affected by other factors [5, 6]. This study has shown the presence of OOS and its risk among the Penang adolescent thalassemia patients. Some were symptomatic. Many were unaware of OOS and took minimal dietary precaution. This calls for better education about OOS, its detection and prevention for thalassemia patients and health-care workers.
- Chatterjee R, Bajoria R: Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment. Hemoglobin. 2009, 33 (S1): S136-S8.PubMedView ArticleGoogle Scholar
- Jensen C, Tuck S, Agnew J, Koneru S, Morris R, Yardumian A, et al: High prevalence of low bone mass in thalassaemia major. British Journal of Haematology. 1998, 103: 911-5.PubMedView ArticleGoogle Scholar
- Voskaridou E, Terpos E: Pathogenesis and management of osteoporosis in thalassemia. Pediatric endocrinology reviews: PER. 2008, 6: 86-93.PubMedGoogle Scholar
- Bianchi ML, Baim S, Bishop NJ, Gordon CM, Hans DB, Langman CB, et al: Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatric Nephrology. 2010, 25 (1): 37-47.PubMedView ArticleGoogle Scholar
- Clark LC, Beck E: Plasma “alkaline” phosphatase activity: I. Normative data for growing children. The Journal of pediatrics. 1950, 36 (3): 335-41.PubMedView ArticleGoogle Scholar
- Schiele F, Henny J, Hitz J, Petitclerc C, Gueguen R, Siest G: Total bone and liver alkaline phosphatases in plasma: biological variations and reference limits. Clinical chemistry. 1983, 29 (4): 634-41.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.